SI1368019T1 - Formulacija esmolola - Google Patents
Formulacija esmololaInfo
- Publication number
- SI1368019T1 SI1368019T1 SI200230444T SI200230444T SI1368019T1 SI 1368019 T1 SI1368019 T1 SI 1368019T1 SI 200230444 T SI200230444 T SI 200230444T SI 200230444 T SI200230444 T SI 200230444T SI 1368019 T1 SI1368019 T1 SI 1368019T1
- Authority
- SI
- Slovenia
- Prior art keywords
- esmolol
- hydrochloride
- esmolol formulation
- formulation
- isopropylamino
- Prior art date
Links
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 title 1
- 229960003745 esmolol Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001015 esmolol hydrochloride Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- GXLJZLBKWSJXFP-UHFFFAOYSA-N phenyl propanoate;hydrochloride Chemical compound Cl.CCC(=O)OC1=CC=CC=C1 GXLJZLBKWSJXFP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/759,547 US6310094B1 (en) | 2001-01-12 | 2001-01-12 | Ready-to-use esmolol solution |
| US10/016,260 US6528540B2 (en) | 2001-01-12 | 2001-10-30 | Esmolol formulation |
| PCT/US2002/000329 WO2002076446A1 (en) | 2001-01-12 | 2002-01-02 | Esmolol formulation |
| EP02736473A EP1368019B2 (en) | 2001-01-12 | 2002-01-02 | Esmolol formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI1368019T1 true SI1368019T1 (sl) | 2007-02-28 |
| SI1368019T2 SI1368019T2 (sl) | 2010-10-29 |
Family
ID=26688377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230444T SI1368019T2 (sl) | 2001-01-12 | 2002-01-02 | Formulacija esmolola |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1368019B2 (sl) |
| JP (1) | JP2004519506A (sl) |
| CN (1) | CN1298320C (sl) |
| AT (1) | ATE341319T1 (sl) |
| AU (1) | AU2002309475B2 (sl) |
| BR (1) | BR0203517A (sl) |
| CA (1) | CA2410446C (sl) |
| CZ (1) | CZ304290B6 (sl) |
| DE (1) | DE60215129T3 (sl) |
| DK (1) | DK1368019T4 (sl) |
| ES (1) | ES2272720T5 (sl) |
| HU (1) | HUP0204520A3 (sl) |
| IL (1) | IL151359A (sl) |
| MX (1) | MXPA03006229A (sl) |
| PL (1) | PL216192B1 (sl) |
| RU (1) | RU2286774C2 (sl) |
| SI (1) | SI1368019T2 (sl) |
| SK (1) | SK288113B6 (sl) |
| TR (1) | TR200202557T1 (sl) |
| TW (1) | TWI277414B (sl) |
| WO (1) | WO2002076446A1 (sl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| EP1417962A1 (de) | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol |
| EP1680144B1 (en) * | 2003-10-08 | 2011-10-05 | Mallinckrodt LLC | Methylphenidate solution and associated methods of administration and production |
| CN1303987C (zh) * | 2004-11-19 | 2007-03-14 | 陈庆财 | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 |
| US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| AU2014203121B2 (en) * | 2007-05-22 | 2016-04-21 | Baxter Healthcare Sa | Concentrate esmolol |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| SI2234614T1 (sl) | 2007-12-21 | 2013-01-31 | Aop Orphan Pharmaceuticals Ag | Farmacevtska zmes za parenteralno administracijo ultra-kratko delujočega blokatorja beta-adrenoreceptorja |
| PT2480204E (pt) | 2009-09-22 | 2014-01-22 | Vlife Sciences Technologies Pvt Ltd | Formulação tópica para úlceras do pé diabético |
| ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
| JP2014511365A (ja) | 2011-01-27 | 2014-05-15 | バクスター・インターナショナル・インコーポレイテッド | 心臓障害の処置に関連する静脈刺激を調節するための（ｓ）−エスモロールの使用 |
| JP2014505074A (ja) | 2011-01-27 | 2014-02-27 | バクスター・インターナショナル・インコーポレイテッド | 血圧低下を最小化しおよび／または制御しながら頻脈を治療しおよび／または心拍数を制御する方法 |
| LT2846776T (lt) | 2012-05-10 | 2020-06-25 | Aop Orphan Pharmaceuticals Ag | Parenterinė esmololio kompozicija |
| US8835505B1 (en) | 2013-03-15 | 2014-09-16 | Welgrace Research Group | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
| CN104473869A (zh) * | 2014-11-20 | 2015-04-01 | 北京京科泰来科技有限公司 | 一种艾司洛尔脂肪乳及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU575153B2 (en) * | 1984-04-09 | 1988-07-21 | Du Pont Merck Pharmaceutical Company, The | Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders |
| US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| CN1074763C (zh) * | 1997-11-13 | 2001-11-14 | 山东省医药工业研究所 | 艾司洛尔盐酸盐的制备方法 |
-
2001
- 2001-12-14 TW TW090131012A patent/TWI277414B/zh not_active IP Right Cessation
-
2002
- 2002-01-02 AT AT02736473T patent/ATE341319T1/de active
- 2002-01-02 ES ES02736473T patent/ES2272720T5/es not_active Expired - Lifetime
- 2002-01-02 HU HU0204520A patent/HUP0204520A3/hu not_active Application Discontinuation
- 2002-01-02 DE DE60215129T patent/DE60215129T3/de not_active Expired - Lifetime
- 2002-01-02 JP JP2002574961A patent/JP2004519506A/ja not_active Withdrawn
- 2002-01-02 CZ CZ2002-3825A patent/CZ304290B6/cs not_active IP Right Cessation
- 2002-01-02 EP EP02736473A patent/EP1368019B2/en not_active Expired - Lifetime
- 2002-01-02 BR BR0203517-0A patent/BR0203517A/pt not_active Application Discontinuation
- 2002-01-02 CA CA002410446A patent/CA2410446C/en not_active Expired - Lifetime
- 2002-01-02 SK SK1278-2002A patent/SK288113B6/sk not_active IP Right Cessation
- 2002-01-02 WO PCT/US2002/000329 patent/WO2002076446A1/en not_active Ceased
- 2002-01-02 PL PL357387A patent/PL216192B1/pl unknown
- 2002-01-02 MX MXPA03006229A patent/MXPA03006229A/es active IP Right Grant
- 2002-01-02 SI SI200230444T patent/SI1368019T2/sl unknown
- 2002-01-02 IL IL151359A patent/IL151359A/en active IP Right Grant
- 2002-01-02 AU AU2002309475A patent/AU2002309475B2/en not_active Expired
- 2002-01-02 RU RU2002132189/15A patent/RU2286774C2/ru active
- 2002-01-02 TR TR2002/02557T patent/TR200202557T1/xx unknown
- 2002-01-02 DK DK02736473.6T patent/DK1368019T4/da active
- 2002-01-02 CN CNB028000676A patent/CN1298320C/zh not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL151359A (en) | Esmolol formulation | |
| EP1738756A3 (en) | Esmolol formulation | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JO2282B1 (en) | Oxazole derivatives | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| DE602004011966D1 (en) | Heterocyclylverbindungen | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| NO20050018L (no) | Lasofoxifentabletter og belegg | |
| EP2269608A3 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| GB0109122D0 (en) | Novel compounds | |
| AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| PL365258A1 (en) | Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions | |
| SE0002354D0 (sv) | New formulation | |
| MXPA03009723A (es) | Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo. | |
| TW200503714A (en) | Pde9 inhibitors for treating type 2 diabetes, metabolic syndrome, and cardiovascular disease |